Detection of minimal residual disease in B lymphoblastic leukemia using viSNE

Publisher： John Wiley & Sons Inc

E-ISSN： 1552-4957|88|5|294-304

ISSN： 1552-4949

Source： Cytometry. Part B: Clinical Cytometry, Vol.88, Iss.5, 2015-09, pp. : 294-304

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A novel flow cytometric assay for detection of residual disease in patients with B‐lymphoblastic leukemia/lymphoma post anti‐CD19 therapy

By  

Cytometry. Part B: Clinical Cytometry, Vol. 94, Iss. 1, 2018-01 ,pp. : 112-120

John Wiley & Sons Inc

Access to resources Recommend Favorite

Evaluation of new markers for minimal residual disease monitoring in B‐cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000–000

By  

Cytometry. Part B: Clinical Cytometry, Vol. 94, Iss. 1, 2018-01 ,pp. : 100-111

John Wiley & Sons Inc

Access to resources Recommend Favorite

Implementation of a simplified flow cytometric assays for minimal residual disease monitoring in childhood acute lymphoblastic leukemia

By  

Cytometry. Part B: Clinical Cytometry, Vol. 94, Iss. 1, 2018-01 ,pp. : 94-99

John Wiley & Sons Inc

Access to resources Recommend Favorite

Monitoring Minimal Residual Disease in AML

By Stewart CC  

Cytotherapy, Vol. 1, Iss. 4, 1999-01 ,pp. : 341-341

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Use of a Tumor-Cell Enrichment Column for the Enhanced Detection of Minimal Residual Disease in the BM or Apheresis Peripheral Blood Transplant Products of Breast-Cancer Patients

By Shammo JM   Smith SL   Bennett MV   Lee HW   Ostrander A   Ross AA   Williams SF  

Cytotherapy, Vol. 1, Iss. 5, 1999-01 ,pp. : 367-376

Ashgate Publishing Ltd

Access to resources Recommend Favorite